Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2019 Apr 23;21(Suppl 2):ii100. doi: 10.1093/neuonc/noz036.150

LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE

Scott Ryall 1,2, Michal Zapotocky 1,3, Kohei Fukuoka 1, Ana Guerreiro-Stucklin 1,4, Julie Bennett 1, Anthony Arnoldo 1, Paul Kowalski 1, Monique Johnson 1, Liana Figueiredo Nobre 1, Alvaro Lassaletta 1,5, Eric Bouffet 1, Ute Bartels 1, David Ellison 6, Ruth Tatevossian 6, Wilda Orisme 6, Ibrahim Qaddoumi 6, Mariarita Santi 7, Lea Surrey 7, Angela Waanders 7, Marilyn Li 7, Matthias Karajannis 8, Stephen Gilheeney 8, Marc Rosenblum 8, Tejus Bale 8, Uri Tabori 1,2, Cynthia Hawkins 1,2
PMCID: PMC6477358

Abstract

Molecular characterization of pediatric low-grade gliomas (pLGG) have identified recurrent alterations, most commonly involving BRAF and NF1, which have been exploited to aid in diagnosis and treatment decisions. However, a significant portion do not have these canonical alterations, and the genetics and clinical course of these tumors remains unknown. We molecularly characterized a cohort of 986 patients diagnosed at SickKids from 1990–2017 with comprehensive long-term clinical data. For the rare non-canonical alterations uncovered, data was supplemented with cases from the Taskforce. Within the SickKids cohort, 72% were driven by canonical alterations in either BRAF (38% fusions, 16% V600E) or NF1 (18%). 11.5% were driven via recurrent non-canonical events involving FGFR1 (6%), FGFR2 (1%), MYB (1%), MYBL1 (1%), H3F3A (2%) or IDH1 (0.5%). The Taskforce supplemented cohort revealed that most FGFR1/2 fusions (n=51) were hemispheric and benign, with no deaths observed. In contrast, FGFR1 activating mutations (n=29) were commonly observed as a second hit, occurred throughout the neuraxis, and at an older age. These tumors were more aggressive, having a poor response to therapy and resulting in death. MYB/MYBL1 alterations (n=19) were seen exclusively in angiocentric gliomas and diffuse astrocytomas, respectively. Both are primarily hemispheric and often occur as massive lesions in childhood, yet have excellent long-term outcome. IDH1 (n=8) was seen mostly in adolescents (15–18 years). Importantly, several had a long history of seizures and presented with small lesions years prior to surgery. While all tumours eventually progressed, some (n=6) are alive up to 13 years post diagnosis. H3F3A driven pLGGs (n=12) progressed early, (median 11 months) and all patients succumbed to their disease. The work here represents the largest cohort of non-canonical pLGGs assembled. Our work supports a diagnostic workflow which includes these alterations, and we provide preliminary clinical features of these tumors to better equip practicing clinicians.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES